Takeda Pharmaceutical Company Limited Deferred Tax Expense Income Recognised In Profit Or Loss
Takeda Pharmaceutical Company Limited (TKPHF) reported Deferred Tax Expense Income Recognised In Profit Or Loss of JPY 71.12 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss · last filed 2025-06-25
| Period end | Deferred Tax Expense Income Recognised In Profit Or Loss 12 month | Deferred Tax Expense Income Recognised In Profit Or Loss 12 month as first filed |
|---|---|---|
| 2025-03-31 | 71.12B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | 198.75B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | 188.53B JPY 20-F · filed 2024-06-26 | |
| 2022-03-31 | 136.11B JPY 20-F · filed 2023-06-28 | |
| 2021-03-31 | 141.89B JPY 20-F · filed 2022-06-29 | |
| 2020-03-31 | 343.90B JPY 20-F · filed 2021-06-29 | |
| 2019-03-31 | 69.07B JPY 20-F · filed 2020-06-24 | 75.72B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 7.26B JPY 20-F · filed 2019-06-27 |